General Information
Venetoclax is an investigational small molecule in advanced stages of approval for the treatment of people with chronic lymphocytic leukemia (CLL), including those with 17p deletion, who have received at least one prior therapy.
About the API
Systematic name
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
Trade name(s)
Venetoclax
Technology
High Potent
Molecular Formula
C45H50ClN7O7S
Molecular Weight
868.4392 g/mol
Physical properties
Powder
Therapeutic category
Oncology
Available formulations
Oral Solid